News

24 June

EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?

5 June

Variations in Prices and Reimbursement of Medicines in the European Union

22 May

HAI Europe Urges EMA Not to Backtrack on Commitments to Clinical Trial Data Transparency

22 May

Act Now or Face Catastrophic Post-antibiotic Era: Global Civil Society Coalition Issues Grave Warning to WHA

22 April

Declaration on Antibiotic Resistance (Antibiotic Resistance Coalition)

3 April

Health Action International Welcomes Adoption of New Clinical Trials Regulation by European Parliament

3 April

Health Action International Applauds Medicines Patent Pool, ViiV Healthcare Licensing Agreement for New HIV Treatment

24 March

The EU-US Trade Agreement – Proposals by Pharmaceutical Industry Undermine European Public Policymaking and Public Health

17 March

EU Regulation on Clinical Trials – Close to the Finish Line

12 March

Corporate Interests Should Not Trump Access to Medicines for EU Citizens in Secret TTIP Negotiations

3 March

2013 Annual Report and Financial Statements

1 March

2013 Annual Report and Financial Statements

1 February

Working Paper 4 – Competition Policy

1 February

Policy Brief 3 – Regulation of Mark-ups in the Pharmaceutical Supply Chain

1 February

Policy Brief 5 – Sales Taxes on Medicines

1 February

Policy Brief 6 – The Role of Health Technology Assessment in Medicine Pricing and Reimbursement

1 February

Policy Brief 2 – The Role of Health Insurance in the Cost-effective Use of Medicines

1 February

Working Paper 1 – External Reference Pricing

1 February

Working Paper 6 – The Role of Health Technology Assessment in Medicine Pricing and Reimbursement

1 February

Policy Brief 4 – Competition Policy

1 February

Policy Brief 1 – External Reference Pricing

1 February

Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines

1 February

Working Paper 5 – Sales Taxes on Medicines

1 February

Working Paper 3: The Regulation of Mark-ups in the Pharmaceutical Supply Chain

1 January

Understanding and Responding To Medicines Promotion

1 December

The Status Quo Wins Again: Selected R&D Demonstration Projects Disappoint, Offer Little Progress (2013)

11 October

EU Regulation on Clinical Trials: Further enhance clinical data transparency

6 October

Transparency of Clinical Trial Data on Medicines in the EU

27 September

Transparency in the Public Interest: How the EMA Policy on Publication and Access to Cinical-trial Data Could Help Save Lives

20 September

Trade, TRIPS+, & Access to Medicines